Phase II study of CQR 1 (Cardio3Biosciences) published in Journal of the American College of Cardiology

Results from a Phase II prospective, multicenter, randomized study to evaluate the feasibility, safety, and efficacy of CQR 1 (formerly C-CURE), from Cardio3Biosciences in the treatment of patients with chronic Heart Failure secondary to ischemic cardiomyopathy have been published in the Journal of the American College of Cardiology. The paper shows a statistically significant improvement in cardiac function for the treated patients, and a statistically significant improvement in 6-minute walk distance for the treated patients.

It concludes that the therapy with CQR-1 was feasible and safe with signals of benefit, meriting further definitive clinical evaluation. See: "Safety and efficacy of cardiac cell therapy: first results of the mess (meta�analysis of cardiac stem cell studies) database including individual patient data of 13 randomized and 3 cohort studies." Mariann Gyongyosi et al. Am Coll Cardiol. 2013;61(10_S):. doi:10.1016/S0735-1097(13)61633-2